SCHEMBL1930736

SCHEMBL1930736

CC(=O)Nc1ccc(OC(=O)CO)cc1

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.70
MEN1 O00255 4/20 0.70
OPRK1 P41145 1/20 0.65
NPSR1 Q6W5P4 1/20 0.60
SMN1; SMN2 Q16637 4/20 0.59
HSD17B10 Q99714 2/20 0.59
TDP1 Q9NUW8 2/20 0.59
LMNA P02545 1/20 0.59
CYP1A2 P05177 1/20 0.59
ALDH1A1 P00352 3/20 0.56
MAPT P10636 2/20 0.56
ESR2 Q92731 1/20 0.55
HPGD P15428 2/20 0.53
HTT P42858 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA9 Q16790 1/20 0.51
TSHR P16473 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12291744 0.89 KMT2A (0.75) KMT2AMEN1OPRK1NPSR1SMN1; SMN2
SCHEMBL9823523 0.86 KMT2A (0.70) KMT2AMEN1OPRK1NPSR1SMN1; SMN2
SCHEMBL12987121 0.84 KMT2A (0.68) KMT2AMEN1OPRK1NPSR1SMN1; SMN2
SCHEMBL12291743 0.84 KMT2A (0.68) KMT2AMEN1OPRK1NPSR1SMN1; SMN2
SCHEMBL3805817 0.84 KMT2A (0.68) KMT2AMEN1OPRK1NPSR1SMN1; SMN2
SCHEMBL668622 0.84 KMT2A (0.68) KMT2AMEN1OPRK1NPSR1SMN1; SMN2
SCHEMBL1929979 0.84 GAA (0.50) KMT2AMEN1OPRK1SMN1; SMN2HSD17B10
SCHEMBL27476119 0.83 OPRK1 (0.66) KMT2AMEN1OPRK1NPSR1SMN1; SMN2
SCHEMBL14808444 0.83 KMT2A (1.00) KMT2AMEN1OPRK1NPSR1SMN1; SMN2
SCHEMBL20769767 0.81 KMT2A (0.64) KMT2AMEN1OPRK1NPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE45548-E1 Functionalized drugs and polymers derived therefrom BEZWADA BIOMEDICAL, LLC (US) 2015-06-09 US disclosed
US-RE45548-E1 Functionalized drugs and polymers derived therefrom BEZWADA BIOMEDICAL, LLC (US) 2015-06-09 US disclosed
US-RE45548-E1 Functionalized drugs and polymers derived therefrom BEZWADA BIOMEDICAL, LLC (US) 2015-06-09 US disclosed
US-8409559-B2 Functionalized drugs and polymers derived therefrom Bezwada Biomedical, Inc. (US) 2013-04-02 US disclosed
US-8409559-B2 Functionalized drugs and polymers derived therefrom Bezwada Biomedical, Inc. (US) 2013-04-02 US disclosed
US-8409559-B2 Functionalized drugs and polymers derived therefrom Bezwada Biomedical, Inc. (US) 2013-04-02 US disclosed
US-8372882-B2 Functionalized phenolic esters and amides and polymers therefrom BEZWADA BIOMEDICAL, LLC (US) 2013-02-12 US disclosed
US-8372882-B2 Functionalized phenolic esters and amides and polymers therefrom BEZWADA BIOMEDICAL, LLC (US) 2013-02-12 US disclosed
US-8372882-B2 Functionalized phenolic esters and amides and polymers therefrom BEZWADA BIOMEDICAL, LLC (US) 2013-02-12 US disclosed
US-20110130448-A1 FUNCTIONALIZED PHENOLIC ESTERS AND AMIDES AND POLYMERS THEREFROM BEZWADA BIOMEDICAL LLC (US) 2011-06-02 US disclosed
US-20100152272-A1 FUNCTIONALIZED DRUGS AND POLYMERS THEREFROM BEZWADA BIOMEDICAL, LLC (US) 2010-06-17 US disclosed
US-20100152272-A1 FUNCTIONALIZED DRUGS AND POLYMERS THEREFROM BEZWADA BIOMEDICAL, LLC (US) 2010-06-17 US disclosed
US-7691364-B2 Functionalized drugs and polymers derived therefrom BEZWADA BIOMEDICAL, LLC (US) 2010-04-06 US disclosed
US-7691364-B2 Functionalized drugs and polymers derived therefrom BEZWADA BIOMEDICAL, LLC (US) 2010-04-06 US disclosed
US-7691364-B2 Functionalized drugs and polymers derived therefrom BEZWADA BIOMEDICAL, LLC (US) 2010-04-06 US disclosed
EP-1931334-A2 FUNCTIONALIZED DRUGS AND POLYMERS DERIVED THEREFROM Bezwada Biomedical LLC (US) 2008-06-18 EP disclosed
WO-2007030538-A2 FUNCTIONALIZED DRUGS AND POLYMERS DERIVED THEREFROM BEZWADA BIOMEDICAL LLC (US) 2007-03-15 WO disclosed
WO-2007030538-A2 FUNCTIONALIZED DRUGS AND POLYMERS DERIVED THEREFROM BEZWADA BIOMEDICAL LLC (US) 2007-03-15 WO disclosed
US-20060172983-A1 Functionalized drugs and polymers derived therefrom BEZWADA BIOMEDICAL, LLC (US) 2006-08-03 US disclosed
US-20060173065-A1 Functionalized phenolic esters and amides and polymers therefrom BEZWADA BIOMEDICAL LLC 2006-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152272-A1 FUNCTIONALIZED DRUGS AND POLYMERS THEREFROM OGFR, LOX, DDO KMT2A 3366/4885MEN1 3970/4885OPRK1 721/4885
US-20060172983-A1 Functionalized drugs and polymers derived therefrom OGFR, LOX, OPRM1 KMT2A 3676/4885MEN1 4307/4885OPRK1 757/4885
US-20060173065-A1 Functionalized phenolic esters and amides and polymers therefrom HAAO, HAO2, HCAR3 KMT2A 2066/4885MEN1 4878/4885OPRK1 737/4885
US-20110130448-A1 FUNCTIONALIZED PHENOLIC ESTERS AND AMIDES AND POLYMERS THEREFROM HAO2, HCAR2, HAAO KMT2A 1798/4885MEN1 4874/4885OPRK1 757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.